Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia
Top Cited Papers
- 1 April 2010
- journal article
- clinical trial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 28 (10) , 1749-1755
- https://doi.org/10.1200/jco.2009.25.3187
Abstract
Purpose New treatments are needed for patients with fludarabine- and alemtuzumab-refractory (FA-ref) chronic lymphocytic leukemia (CLL) or patients with fludarabine-refractory CLL with bulky (> 5 c...Keywords
This publication has 32 references indexed in Scilit:
- Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports projectBlood, 2009
- Progressive multifocal leukoencephalopathy in a patient with follicular lymphoma treated with multiple courses of rituximabLeukemia & Lymphoma, 2009
- Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 studyBlood, 2008
- Progressive multifocal leukoencephalopathy after rituximab in a patient with relapsed follicular lymphoma and low IgG levels and a low CD4+lymphocyte countLeukemia & Lymphoma, 2008
- The natural history of fludarabine-refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathyLeukemia & Lymphoma, 2007
- Routine clinical use of alemtuzumab in patients with heavily pretreated B‐cell chronic lymphocytic leukemiaCancer, 2006
- Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemiaBlood, 2005
- Chemoimmunotherapy With Fludarabine, Cyclophosphamide, and Rituximab for Relapsed and Refractory Chronic Lymphocytic LeukemiaJournal of Clinical Oncology, 2005
- Early Results of a Chemoimmunotherapy Regimen of Fludarabine, Cyclophosphamide, and Rituximab As Initial Therapy for Chronic Lymphocytic LeukemiaJournal of Clinical Oncology, 2005
- Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomasBlood, 2004